LYRA News and Press, Lyra Therapeutics Inc. From 02/06/23

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-s...

Lyra Therapeutics press release ( NASDAQ: LYRA ): Q3 GAAP EPS of -$0.40 beats by $0.04 . Revenue of $0.36M (+3500.0% Y/Y) beats by $0.16M . For further details see: Lyra Therapeutics GAAP EPS of -$0.40 beats by $0.04, revenue of $0.36M beats by $0.16M

-- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS); Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All Clinical Trial Supply to Leverage its In-House Expertise and Capabilities; Tem...

The following slide deck was published by Lyra Therapeutics, Inc. in conjunction with this event. For further details see: Lyra Therapeutics (LYRA) Presents At 68th Annual Meeting of the American Rhinologic Society - Slideshow

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study PR Newswire 21-point (37%) mean improvement in SNOT-22 total score at six weeks during the uncontrolled Part 1 stage of the...

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting PR Newswire Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no sympto...

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients PR Newswire ENLIGHTEN II is the second of two Phase 3 trials enrolling surgically-naïve CRS patients in the Global ENLIGHTEN cli...

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 PR Newswire WATERTOWN, Mass. , Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc . (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics compa...

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting PR Newswire WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-s...

Lyra Therapeutics press release ( NASDAQ: LYRA ): Q2 GAAP EPS of -$0.43. Revenue of $0.4M. Cash and cash equivalents as of June 30, 2022 were $120.7 million, compared with $33.8 million at March 31, 2022. The Company expects its cash and c...